sepiapterin (Sephience)
Jump to navigation
Jump to search
Introduction
yellow fluorescing pigment
Pathology
- accumulates in brain with sepiapterin reductase deficiency
Pharmacology
- FDA approved to treat patients with phenylketonuria[2]
Physiology
- intermediate in the salvage pathway of tetrahydrobiopterin
Laboratory
More general terms
References
- ↑ PubChem: 65253
- ↑ 2.0 2.1 Choudhury K, Santhosh C US FDA approves PTC Therapeutics' metabolic disorder drug Reuters. July 28, 2025 https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-ptc-therapeutics-metabolic-disorder-drug-2025-07-28/